Disclaimer
The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.
Board Report (18 March 2024) – Art. 7.198 juncto Art. 7.179 and Art. 7.191 BCAC
Statutory Auditor Report (18 March 2024) – Art. 7.198 juncto Art. 7.179 and Art. 7.191 BCAC
Board Report (22 April 2024) – Art. 7.179 and 7.197 BCAC
Statutory Auditor Report (22 April 2024) – Art. 7.179 BCAC
Statutory Auditor Report (22 April 2024) – Art. 7.197 BCAC
Board Report (24 April 2023) – Art. 7.198 juncto Art. 7.179, Art 7.180 and Art. 7.191 BCAC
20 December 2024
Sequana Medical announces results of Extraordinary General Meeting of Shareholders and update on Convertible Financing
6 December 2024
Sequana Medical announces decision of major shareholders to invest in second tranche of convertible bridge loan
23 October 2024
Sequana Medical announces additional convertible financing of up to EUR 1.0 million from existing investors
30 September 2024
Sequana Medical announces convertible financing of up to EUR 6.1 million from major shareholders
21 March 2024
Sequana Medical successfully raises EUR 11.5 million in an equity placement
20 March 2024
Sequana Medical launches equity placement and provides trading update
Email: IR@sequanamedical.com
Tel: +32 498 053579